SurModics (SRDX) Tops Q3 EPS by 25c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Surmodics Reports Third Quarter Fiscal 2016 Results
July 28, 2016 7:30 AM EDTGAAP Revenue of $20.0 Million, up 25% GAAP EPS of $0.30, Non-GAAP EPS of $0.37 Core Business Performs Well as Key Strategic Growth Priorities Advance Raises Fiscal 2016 Revenue and EPS Guidance
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2016 third quarter, ended June 30, 2016.
Surmodics continued to advance all key strategic growth priorities... More
